{"id":"https://genegraph.clinicalgenome.org/r/72a9806a-3186-48ea-9067-1164cace7556v1.1","type":"EvidenceStrengthAssertion","dc:description":["The SLC30A2 gene, encoding zinc transporter 2 (ZnT2), plays a crucial role in zinc transport from secretory vesicles into breast milk in mammary gland epithelial cells via the JAK2/STAT5 pathway (PMID: 19496757, 19494234). \n\nSLC30A2 was first reported in relation to transient neonatal zinc deficiency (TNZD) in 2006 (Chowanadisai et al., PMID: 17065149). Affected infants are exclusively breastfed. Clinical manifestations include low serum zinc, skin lesions, dermatitis, erythema, alopecia, diarrhea, and failure to thrive, resembling acrodermatitis enteropathica (AE). Zinc supplements resolve symptoms without relapse after weaning. TNZD exhibits incomplete penetrance and variable expressivity, with some exclusively breastfed infants showing mild or no symptoms (PMID: 22733820). The condition typically follows an autosomal dominant inheritance pattern, though compound heterozygous and homozygous variants have been reported in mothers of early-onset TNZD infants (PMID: 23741301, 32278324). Eleven unique variants, including missense, nonsense, and frameshift mutations, documented in 13 unrelated mothers whose infants affected with TNZD across 10 publications (PMIDs: 17065149, 36967740, 22733820, 24194756, 24456035, 27304099, 28111782, 37082517, 23741301, 32278324) are included in this curation. The pathogenic mechanism involves loss-of-function through haploinsufficiency or dominant negative effects.\n\nExperimental evidence further supports this gene-disease association. Knockout (KO) mice studies revealed higher cytoplasmic zinc levels in mammary gland cells compare to wildtype (WT) littermates, with altered zinc localization and accumulation (PMID: 25851903). These results are consistent with in vitro knockdown studies using siRNA in HC11 cells demonstrating cytoplasmic zinc trapping. In addition, ZnT2 null mice demonstrated reduction in milk zinc concentration and significantly lower litter survival (PMID: 25851903). Experimental studies on the TNZD associated variants including p.His54Arg, p.Gly87Arg, p.Gly280Arg, p.Thr312Met, p.Glu355Gln, p.Asp227Asn, p.Glu88Lys, p.Trp152Arg and p.Ser296Leu demonstrated various functional alterations including reduced zinc transport activity and secretion, zinc retention and mislocalization, decreased protein stability, and impaired dimerization in cell models (PMID: 17065149, 36967740, 22733820, 27137936, 23741301, 32278324). In addition, the c.838G>A p.Gly280Arg variant demonstrated aberrant splicing efficiency (PMID: 27304099).\n\nIn summary, there is definitive evidence to support the relationship between autosomal dominant loss of function variants in SLC30A2 and TNZD. This classification was approved by the This classification was approved by the ClinGen IEM GCEP on January 24, 2025 (SOP Version 11). ","The SLC30A2 gene, encoding zinc transporter 2 (ZnT2), plays a crucial role in zinc transport from secretory vesicles into breast milk in mammary gland epithelial cells via the JAK2/STAT5 pathway (PMID: 19496757, 19494234). \n\nSLC30A2 was first reported in relation to transient neonatal zinc deficiency (TNZD) in 2006 (Chowanadisai et al., PMID: 17065149). Affected infants are exclusively breastfed. Clinical manifestations include low serum zinc, skin lesions, dermatitis, erythema, alopecia, diarrhea, and failure to thrive, resembling acrodermatitis enteropathica (AE). Zinc supplements resolve symptoms without relapse after weaning. TNZD exhibits incomplete penetrance and variable expressivity, with some exclusively breastfed infants showing mild or no symptoms (PMID: 22733820). The condition typically follows an autosomal dominant inheritance pattern, though compound heterozygous and homozygous variants have been reported in mothers of early-onset TNZD infants (PMID: 23741301, 32278324). Eleven unique variants, including missense, nonsense, and frameshift mutations, documented in 13 unrelated mothers whose infants affected with TNZD across 10 publications (PMIDs: 17065149, 36967740, 22733820, 24194756, 24456035, 27304099, 28111782, 37082517, 23741301, 32278324) are included in this curation. The pathogenic mechanism involves loss-of-function through haploinsufficiency or dominant negative effects.\n\nExperimental evidence further supports this gene-disease association. Knockout (KO) mice studies revealed higher cytoplasmic zinc levels in mammary gland cells compare to wildtype (WT) littermates, with altered zinc localization and accumulation (PMID: 25851903). These results are consistent with in vitro knockdown studies using siRNA in HC11 cells demonstrating cytoplasmic zinc trapping. In addition, ZnT2 null mice demonstrated reduction in milk zinc concentration and significantly lower litter survival (PMID: 25851903). Experimental studies on the TNZD associated variants including p.His54Arg, p.Gly87Arg, p.Gly280Arg, p.Thr312Met, p.Glu355Gln, p.Asp227Asn, p.Glu88Lys, p.Trp152Arg and p.Ser296Leu demonstrated various functional alterations including reduced zinc transport activity and secretion, zinc retention and mislocalization, decreased protein stability, and impaired dimerization in cell models (PMID: 17065149, 36967740, 22733820, 27137936, 23741301, 32278324). In addition, the c.838G>A p.Gly280Arg variant demonstrated aberrant splicing efficiency (PMID: 27304099).\n\nIn summary, there is definitive evidence to support the relationship between autosomal dominant loss of function variants in SLC30A2 and TNZD. This classification was approved by the ClinGen IEM GCEP on January 24, 2025 (SOP Version 11). "],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/72a9806a-3186-48ea-9067-1164cace7556","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2025-03-28T16:35:01.595Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":["2025-01-24T05:00:00.000Z","2025-01-24T17:00:00.000Z"],"role":"Approver"}],"curationReasonDescription":"The SLC30A2 c.839G>T p.Gly250Val variant was reported in another mother who was exclusively breastfeeding her infant, presenting with TNZD symptoms. This was documented in a publication by Golan Y, Yerushalmi B, Efrati E, and Assaraf YG (2017) titled \"Identification of Genetic Diseases Using Breast Milk Cell Analysis: The Case of Transient Neonatal Zinc Deficiency (TNZD)\" in Cell Mol Med, Vol. 3 No. 2: 8, which lacks a PMID.\nFunctional studies in maternal breast milk cells demonstrated that the c.839G>T alteration resulted in a small deletion of 9 amino acids (Î”9AA) in ZnT2 (Fig 2), which failed to dimerize with the wild-type protein (Fig 4). The mutant protein exhibited enhanced degradation (Fig 6) and a complete loss of zinc transport activity, as evidenced by intracellular zinc accumulation (Fig 6). This case report, along with the functional studies, contributed an additional 0.5 points for case evidence, bringing the total score to 12.15.","curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06fcb6db-c5ef-4a21-959d-b76d02fcf0be","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06fcb6db-c5ef-4a21-959d-b76d02fcf0be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37082517","allele":{"id":"https://genegraph.clinicalgenome.org/r/46c53033-3572-4e85-85be-f51e320e724c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.927G>C (p.Trp309Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339096617"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e019de67-140f-44e1-bd37-e3c05a31d1d2","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e019de67-140f-44e1-bd37-e3c05a31d1d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24456035","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e96a2bc-d336-45b5-9f6e-23c8e1a9afd9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.663del (p.Phe221LeufsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA521905265"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/aa982431-9a1a-4088-bfde-cdf9893f5708","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa982431-9a1a-4088-bfde-cdf9893f5708_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28111782","allele":{"id":"https://genegraph.clinicalgenome.org/r/f5d81d6b-600e-41d8-8482-d1a3e1f5daf9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.1063G>C (p.Glu355Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339095891"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bde97ec0-a050-41bc-94ca-68e0abed22bc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bde97ec0-a050-41bc-94ca-68e0abed22bc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27304099","allele":{"id":"https://genegraph.clinicalgenome.org/r/6fbb29d6-5def-41f6-b212-716c300e30d7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.935C>T (p.Thr312Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339096577"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/bde97ec0-a050-41bc-94ca-68e0abed22bc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"1. these mutants can't reserve TD40 zinc sensitive phenotype, the vesicular zinc level was lower that that in WT, indicating that all three mutations result in a lack of zinc transport activity. fig 3\t\t\n2. The protein level was reduduced when the protein expression was inhibited after 4-8 hur, sugesting mutant proteins are unstable. Fig 4a\t\t\n3. immunoprecipitation analysis indicated that all three ZnT2 mutants can form dimers with WT, indicating dominant-negative mechnism, fig 4b\t\t\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/425bb561-b7ed-4707-b9c4-8f63f0124383","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/425bb561-b7ed-4707-b9c4-8f63f0124383_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23741301","allele":{"id":"https://genegraph.clinicalgenome.org/r/1279ad5f-cc63-4745-aca6-0d4debfddb05","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.454T>C (p.Trp152Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339101577"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/425bb561-b7ed-4707-b9c4-8f63f0124383_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"1. Stable expression of W152R in zinc sensitive DT40 cells which can't survive in the presence of 60 uM zinc can't reverse zinc sensitive phenotype which WT ZnT2 does (Table 1).\n2. MT activity was reduced in WT but increased in W152R mutant cells, indicating W152R mutant lost the function of transporting zinc into vesicles, therefore free zinc in cytoplams binded with MT. Fig 4C\n3.W152R demonstrated instable protein by Western blot. Fig 6, 7\t\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/16027fbc-5c2d-47bd-af08-012fadae7904","type":"EvidenceLine","dc:description":"Although S296L was instable and weakly interacted with WT, the zinc transport activity was similar to WT. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16027fbc-5c2d-47bd-af08-012fadae7904_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23741301","allele":{"id":"https://genegraph.clinicalgenome.org/r/128fa475-b0d4-4839-abac-9e9c2c5bdea8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.887C>T (p.Ser296Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339096789"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/16027fbc-5c2d-47bd-af08-012fadae7904_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"1. S296L demonstrated instable protein by Western blot, Lysosomal or proteasome inhibitors blocked the degradation of the S296L mutant. Fig 6\n2. S296L weakly interacted with WT. Fig5\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/932038ff-144f-415f-b3ce-45bb2cbf2d74","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/932038ff-144f-415f-b3ce-45bb2cbf2d74_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24194756","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd946529-7e12-40ba-ab72-2c782326f29f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.259G>A (p.Gly87Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA699349"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3e31976c-e16d-40a2-9b9f-29eafa27b354","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e31976c-e16d-40a2-9b9f-29eafa27b354_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36967740","allele":{"id":"https://genegraph.clinicalgenome.org/r/4cc527d3-ad8b-4770-9688-56ba2c0d4ac2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.679G>A (p.Asp227Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA19730458"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3e31976c-e16d-40a2-9b9f-29eafa27b354_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"stable expression of D227N mutant failed to rescue zinc sensitive phenotype of TD40 cells, indicating the D227N mutant is a loss of function variant. Fig1 C, D\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/13c29c9d-6dbb-42d8-ab0a-ce82cb7835c4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13c29c9d-6dbb-42d8-ab0a-ce82cb7835c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27304099","allele":{"id":"https://genegraph.clinicalgenome.org/r/f5d81d6b-600e-41d8-8482-d1a3e1f5daf9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/13c29c9d-6dbb-42d8-ab0a-ce82cb7835c4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"1. this  mutant can't reserve TD40 zinc sensitive phenotype, the vesicular zinc level was lower that that in WT, indicating that all three mutations result in a lack of zinc transport activity. fig 3\t\n2. The protein level was reduduced when the protein expression was inhibited after 4-8 hur, sugesting mutant proteins are unstable. Fig 4a\t\n3.immunoprecipitation analysis indicated that all three ZnT2 mutants can form dimers with WT, indicating dominant-negative mechnism, fig 4b\t\t\n\t\n\t\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/caeb7412-cfef-4045-a30b-f30454da1696","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/caeb7412-cfef-4045-a30b-f30454da1696_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22733820","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd946529-7e12-40ba-ab72-2c782326f29f"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/caeb7412-cfef-4045-a30b-f30454da1696_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"mutant ZnT2 resulted in reduced zinc accumulation, reduced zinc secretion and increased cytoplasmic zinc retention in Fig6\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c3a60af3-bd7f-4ae3-97ec-f82b3a657007","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3a60af3-bd7f-4ae3-97ec-f82b3a657007_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32278324","allele":{"id":"https://genegraph.clinicalgenome.org/r/bedc3a3c-cf01-4fb8-a024-84508bf92ebf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.262G>A (p.Glu88Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339104054"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/c3a60af3-bd7f-4ae3-97ec-f82b3a657007_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"mutant caused significant zinc retention and reduced zinc secretion in transfected HEK293 cells demonstrated by zinc fluorescence. Fig 2, 3B\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b3394572-79c6-4bf7-8d67-191847cf9727","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b3394572-79c6-4bf7-8d67-191847cf9727_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27304099","allele":{"id":"https://genegraph.clinicalgenome.org/r/4077ac87-bf3d-472d-a79d-2faef83a9b97","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.838G>A (p.Gly280Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339097621"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b3394572-79c6-4bf7-8d67-191847cf9727_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"(RT)-PCR analysis using ZnT2 cDNA constructs containing intron 6 (Figure 2a) indicated that it reduced the splicing efficiency of the ZnT2 transcript to almost one-fourth that of the wild-type sequence (Figure 2b). Thus, the c.838G>A mutation results in reduced splicing efficiency of intron 6, and causes substitution p.G280R in the ZnT2 protein when intron 6 is spliced out.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1e7d6ef6-884d-47fc-8f1e-9e932d5e4e8e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e7d6ef6-884d-47fc-8f1e-9e932d5e4e8e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17065149","allele":{"id":"https://genegraph.clinicalgenome.org/r/9dcf178e-c747-4056-8b2f-bbce77d904c9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001004434.3(SLC30A2):c.161A>G (p.His54Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA006481"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1e7d6ef6-884d-47fc-8f1e-9e932d5e4e8e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"1. zinc secretion was reduced in HEK293 cells overexpression of H54R mutant comparing to control group, suggesting mutant ZnT2 lost its function Fig6\n2. co-transfection of the WT and H54R mutant didn't abolish the increased zinc secretion resulted from the WT alone, suggest the mechanism of H54R mutant was not dominant negative.Fig7 \t\n3.Western blot revealed the decreased ZnT2 protein comparing to WT, Fig8A \t\n4. immunostaining study revealed the mutant protein accumulated at the perinuclear region fig9, which imparied the normal fimction of ZnT2\t\n\n\t\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/00b79c88-14a3-4ebd-be61-fc9b02934175","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00b79c88-14a3-4ebd-be61-fc9b02934175_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22733820","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd946529-7e12-40ba-ab72-2c782326f29f"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/00b79c88-14a3-4ebd-be61-fc9b02934175_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"mutant ZnT2 resulted in protein trapped or accumulated in intracellular compartments, failed to locaized in secretoary vesicles and imparied zinc homeostasis.\n","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":7.65},{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc3ba337-d0fd-45a9-af47-c2e4a8388df2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8f553057-0a96-4c6f-a8e2-f9ae382b1dc0","type":"Finding","dc:description":"ZnT2 protein resides in secretory vesicles and plays the primary role in Zn secretion from the mammary epithelial cells. Loss of function impairs zinc homeostasis and secretion of zinc into milk which leads to breast milk zinc deficiency","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19496757","rdfs:label":"ZnT2 involved in zinc accumulation and secretion ","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3d30ee8c-9d31-4a9a-bad7-ec45dd7936b4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e37ff202-cba0-4815-9cc8-ffd2883bbbb8","type":"Finding","dc:description":"Loss of ZnT2 function leads to decreased zinc in milk during lactation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19494234","rdfs:label":"ZnT2 is upregulated in mammary epithelial cells","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/504ccf7f-0317-482f-8293-ec82488c060a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffea5e59-9183-4afa-9b69-b17732afe6e7","type":"Finding","dc:description":"Accumulation of zinc in cytoplasm in mammary gland cells impaired the zinc secretion into the milk. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25851903","rdfs:label":"ZnT2 involved in transport zinc into secretory vesicles","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0d836749-72d2-4496-96e6-41de21e7505e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b9422e7-7924-48a5-ac6b-56cda051e02b","type":"FunctionalAlteration","dc:description":"Transfection of G280R, T312M or E355Q mutant in human MCF-7 cells demonstrated a dosage-dependent reduction of  zinc transport activity comparing to wt, suggesting these mutant led to loss of the ZnT2 normal function.\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27137936","rdfs:label":"TNZD mutants impaired zinc transport"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/36642f25-0319-4472-b7e9-777d8d5db50c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb7c39ae-8d0e-41cc-9bdb-71a31dd8d455","type":"FunctionalAlteration","dc:description":"1. G280R, T312M and E355Q mutants retained ZnT2 protein in the ER in different degrees in human MCF-7 cells. \n2. Mutant proteins failed to rescue cell survival which could be partially rescued by co-transfection with WT, indicating the mechnism is unlikely dominant negative expecially compared with G87R mutant. \n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27137936","rdfs:label":"Mutants impaired subcellular localization and cell survival"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/25f55750-1ef6-4aad-b42b-fbc00b67b258","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42ce272e-403c-4058-84f3-dfa874bae360","type":"FunctionalAlteration","dc:description":"WT ZnT2 is localized in secretary vesicles G87R ZnT2 largely localized in perinuclear regions.\n\nCo-transfection of G87R and WT resulted in mislocalization of ZnT2 and its retention in a perinuclear region in majority of cells, suggesting dominant negative mechanism.\n\nCo-transfection of G87R and WT resulted in reduced zinc secretion similar to G87R alone or vector.\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22733820","rdfs:label":"G87R resulted in loss of ZnT2 function via dominant negative"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c4bde390-ff71-42de-949c-2ebd37f18b1a_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf12600a-baf2-4c19-92b1-e367bc2673ea","type":"EvidenceLine","dc:description":"The results were observed on null mice but TNZD is an AD disease in human","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23046e12-c7fc-4fce-b9bb-e57ed107bbca","type":"Finding","dc:description":"Zinc concentration is comparable in wt and null mice in the nulliparous state. During lactation, zinc was increased in mice with both genotypes. Additionally, zinc level in null mice is higher than in WT. Higher MT expression suggested zinc was trapped in cytoplasm without ZnT2 function. Staining of zinc in mammary glad cells also demonstrated zinc accumulation in cytoplasm instead of vesicles. \nZnT2 null mice presented with lower level of zinc as well as low lever of fat, casein, and lactose. Total yield of milk was reduced comparing to WT littlemates. Additionally, ZnT2 null mice showed a higher no survival rate. Taken together, ZnT2 is a critical regulator of mammary gland differentiation and milk secretion during lactation, which is crucial for sustaining infant health.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25851903","rdfs:label":"Abnormal zinc accumulation in ZnT2 null mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":10139,"specifiedBy":"GeneValidityCriteria11","strengthScore":11.65,"subject":{"id":"https://genegraph.clinicalgenome.org/r/OLGej00Yt1c","type":"GeneValidityProposition","disease":"obo:MONDO_0011973","gene":"hgnc:11013","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c4bde390-ff71-42de-949c-2ebd37f18b1a-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}